PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9733598-12	1998	CONCLUSION: IM inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice.	Tetradecanoylphorbol Acetate	64-67	fibroblast growth factor 2	Mus musculus	24-28	
9704334-10	1998	Phorbol 12-myristate 13-acetate (PMA, 2 or 5 nM) protected CCE cells against apoptosis induced by the introduction of TGF-beta 1 and withdrawal of aFGF, bFGF or VEGF, while H7 (50 microM), but not HA1004 (50 microM), abrogated the protective effect of PMA on CCE apoptosis.	Tetradecanoylphorbol Acetate	33-36	fibroblast growth factor 2	Mus musculus	153-157	
7718627-7	1995	Down-regulation of protein kinase C (PKC) activity by TPA pretreatment repressed the bFGF induction of TIS1 but had little effect on the bFGF-stimulated expression of TIS8.	Tetradecanoylphorbol Acetate	54-57	fibroblast growth factor 2	Mus musculus	85-89	
9704334-10	1998	Phorbol 12-myristate 13-acetate (PMA, 2 or 5 nM) protected CCE cells against apoptosis induced by the introduction of TGF-beta 1 and withdrawal of aFGF, bFGF or VEGF, while H7 (50 microM), but not HA1004 (50 microM), abrogated the protective effect of PMA on CCE apoptosis.	Tetradecanoylphorbol Acetate	0-31	fibroblast growth factor 2	Mus musculus	153-157	
10412048-9	1999	12-O-Tetradecanoylphorbol-13-acetate, an activator of PKC, attenuated the phosphorylation of p38 MAP kinase by bFGF, but did not affect the A23187-induced phosphorylation.	Tetradecanoylphorbol Acetate	0-36	fibroblast growth factor 2	Mus musculus	111-115	
10091935-5	1998	TPA-treated B16F1 cells showed enhanced release of basic FGF (bFGF) and vascular endothelial growth factor (VEGF) and increased angiogenic capacity and lung colony formation in vivo.	Tetradecanoylphorbol Acetate	0-3	fibroblast growth factor 2	Mus musculus	51-60	
10091935-5	1998	TPA-treated B16F1 cells showed enhanced release of basic FGF (bFGF) and vascular endothelial growth factor (VEGF) and increased angiogenic capacity and lung colony formation in vivo.	Tetradecanoylphorbol Acetate	0-3	fibroblast growth factor 2	Mus musculus	62-66	
10091935-7	1998	However, both cell lines showed an induction of VEGF as well as bFGF expression by TPA treatment suggesting that in BL6 cells antagonistic factors, inhibiting the angiogenic and metastatic capacity, are induced by this treatment.	Tetradecanoylphorbol Acetate	83-86	fibroblast growth factor 2	Mus musculus	64-68